Table 1 Demographic characteristics, risk factors, and prognosis of patients with fluconazole resistant and fluconazole susceptible C. parapsilosis
Fluconazole resistant C. parapsilosis (n = 88) | Fluconazole sensitive C. parapsilosis (n = 85) | p value | |
|---|---|---|---|
Demographic features | |||
Age years, median (IQR) | 62.5 (1–91) | 55 (1–85) | 0.027 |
Age 0–- 1 years, n (%) | 6 (6.8%) | 8 (9.4%) | |
Age 2–- 17 years, n (%) | 9 (10.2%) | 10 (11.8%) | 0.115 |
Age 18–- 65 years, n (%) | 36 (40.9%) | 46 (54.1%) | |
Age ≥ 66 years, n (%) | 37 (42.0%) | 21 (24.7%) | |
Sex male, n (%) | 50 (56.8%) | 46 (51.1%) | 0.721 |
Hospital Admitted | |||
Ward | 78 (88.6%) | 73 (85.9%) | 0.652 |
Intensive Care Unit | 10 (11.4%) | 12 (14.1%) | 0.652 |
Patients’ underlying diseases | |||
Diabetes Mellitus, n (%) | 10 (11.4%) | 10 (11.8%) | 0.934 |
Hypertension, n (%) | 6 (6.8%) | 16 (18.8%) | 0.018 |
Asthma/COPD, n (%) | 5 (5.7%) | 4 (4.7%) | 1.000 |
Hematological malignancy, n (%) | 17 (19.3%) | 6 (7.1%) | 0.018 |
Solid organ malignancy, n (%) | 9 (10.2%) | 6 (7.1%) | 0.459 |
GI malignancy, n (%) | 42 (47.7%) | 21 (24.7%) | 0.002 |
GI Diseases, n (%) | 23 (26.1%) | 12 (14.1%) | 0.049 |
CVD, n (%) | 21 (23.9%) | 10 (11.8%) | 0.038 |
Hepatobiliary system diseases, n (%) | 7 (8.0%) | 5 (5.9%) | 0.592 |
CNS Diseases, n (%) | 13 (14.8%) | 5 (5.9%) | 0.056 |
Abdominal Operation, n (%) | 38 (43.2%) | 23 (27.1%) | 0.026 |
Burn, n (%) | 11 (12.5%) | 6 (7.1%) | 0.229 |
Invasive Procedures | |||
CVC, n (%) | 85 (96.6%) | 38 (44.7%) | < 0.001 |
TPN, n (%) | 70 (79.5%) | 38 (44.7%) | < 0.001 |
TPN duration (> 3 days), n (%) | 51 (72.9%) | 21 (55.3%) | 0.064 |
Urinary Catheter, n (%) | 76 (86.4%) | 58 (68.2%) | 0.004 |
Nephrostomy Catheter, n (%) | 4 (4.5%) | 3 (3.5%) | 1.000 |
Colostomy, n (%) | 22 (25.0%) | 10 (11.8%) | 0.025 |
History of hospitalization in the last 3 months, n (%) | 56 (63.6%) | 38 (44.7%) | 0.012 |
Length of stay in hospital, median (IQR) | 11 (0–94) | 13 (0–37) | 0.259 |
Chemotherapy treatment, n (%) | 26 (29.5%) | 17 (20.0%) | 0.146 |
Neutropenia, n (%) | 14 (15.9%) | 13 (15.3%) | 0.911 |
Sepsis-1, n (%) | 9 (10.2%) | 5 (5.9%) | 0.295 |
Antimicrobial exposure in the last 90 days | |||
Carbapenem, n (%) | 58 (65.9%) | 60 (70.6%) | 0.509 |
Glycopeptide, n (%) | 44 (50.0%) | 44 (51.8%) | 0.816 |
4th generation cephalosporin, n (%) | 12 (13.6%) | 12 (14.1%) | 0.927 |
3rd generation cephalosporin, n (%) | 2 (2.3%) | 4 (4.7%) | 0.438 |
Fluoroquinolone, n (%) | 7 (8.0%) | 5 (5.9%) | 0.592 |
Aminoglycoside, n (%) | 17 (19.3%) | 15 (17.6%) | 0.777 |
Colistin, n (%) | 11 (12.5%) | 10 (11.8%) | 0.882 |
Tigecycline, n (%) | 4 (4.5%) | 4 (4.7%) | 1.000 |
Anti-pseudomonal penicillin, n (%) | 8 (9.1%) | 3 (3.5%) | 0.134 |
Linezolid, n (%) | 10 (11.4%) | 10 (11.8%) | 0.934 |
Daptomycin, n (%) | 5 (5.7%) | 1 (1.2%) | 0.211 |
Trimethoprim-sulfomethoxazole, n (%) | 8 (9.1%) | 9 (10.6%) | 0.741 |
Fluconazole, n (%) | 20 (22.7%) | 19 (22.4%) | 0.953 |
Prognosis | |||
Death, n (%) | 19 (21.5%) | 7 (8.2%) | 0.014 |
Microbiological Cure, n (%) | 72 (81.8%) | 82 (93.1) | 0.002 |
Microbiological Curing Time days, median (IQR) | 3 (1–33) | 2 (1–12) | 0.476 |